drugset / Trial / NCT00748553
A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to test whether treatment of patients with advanced or metastatic solid tumors or breast cancer with Abraxane plus Vidaza is safe and results in good tumor response. All patients enrolling in this study will receive treatment with Abraxane and Vidaza. Safety will be assessed by adverse events, laboratory results and performance status. Tumor response will be measured by RECIST criteria.
Timeline
- Start
- 2008-09
- Primary completion
- 2015-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 50 mg/m2 | — |
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Subject | Azacitidine | Other / unclassified | 100 mg/m2 | — |
| Subject | Nab-paclitaxel | Small molecule | 100 mg/m2 | — |